

**Fig. 1** A significant correlation was observed between the serum PCT level and the Ranson score ( $r = 0.5841$ ,  $p = 0.0022$ ).

their disease.

The severity of pancreatitis was graded according to the Ranson scoring system<sup>16)</sup>. Multiple organ dysfunction syndrome (MODS) was diagnosed according to the diagnostic criteria of ACCP/SCCM<sup>17)</sup>.

Serum PCT was determined by chemoluminescence immunoassay (LUMI test PCT<sup>R</sup>, BRAHMS Diagnostica GmbH, Berlin, Germany). The detection limit was 0.1 ng/mL.

Serum tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) was determined by enzyme-linked immunosorbent assay (ELISA) (Medgenix Diagnostics, Fleurus, Belgium). The detection limit was 3 pg/mL.

Mann-Whitney's U test was used to determine differences between the two groups. Pearson's equation was used to evaluate correlations. For both, the level of significance was defined as  $p < 0.05$ .

### Results


A significant correlation was observed between the serum PCT level and the Ranson score at admission (**Fig. 1**), between the serum TNF- $\alpha$  level and the Ranson score at admission

( $r = 0.5718$ ,  $p = 0.0028$ ), and between the serum PCT level and serum TNF- $\alpha$  level at admission ( $r = 0.6083$ ,  $p = 0.0013$ ) (**Fig. 2**).


Twelve of the patients developed MODS, while the remaining 13 patients did not. The serum PCT level was  $13.6 \pm 14.3$  ng/mL in the patients who developed MODS, and  $1.6 \pm 2.6$  ng/mL in those who did not; the level in the former group was significantly higher (**Fig. 3**).

The serum TNF- $\alpha$  level was  $140.8 \pm 89.2$  pg/mL in the patients who developed MODS, and  $54.4 \pm 34.3$  pg/mL in those who did not; the level in the former group was significantly higher ( $p = 0.001$ ).


Eight patients died and 17 survived while under observation. The PCT level was  $17.7 \pm 15.7$  ng/mL in the patients who died, and  $2.5 \pm 4.1$  ng/mL in those who survived; the level was significantly higher in those who died than in those who survived (**Fig. 4**). The serum TNF- $\alpha$  level was  $151.2 \pm 99.7$  pg/mL in the patients who died, and  $69.8 \pm 51.6$  pg/mL in those who survived; the level in those who died was significantly higher.



**Fig. 2** A significant correlation was noted between the serum PCT level and the serum TNF-α level ( $r = 0.6083$ ,  $p = 0.0013$ ).



**Fig. 3** The serum PCT level in the patients who developed MODS was significantly higher than that in those who did not develop MODS.



**Fig. 4** The serum PCT level in the patients who died was significantly higher than that in those who survived.

### Discussion

Increase in the PCT level in the blood up to 100 ng/mL or more has been reported in cases of severe infections complicated by sepsis.

However, the cells producing PCT have yet to be identified. Elevation of the serum PCT triggered by infection has been reported even in cases who have undergone total thyroid-

ecotmy<sup>18)</sup>.

In cases of injury, the serum PCT level has been reported to transiently increase in the early stage after injuries, depending on the severity<sup>19)</sup>. Serum PCT levels have been reported to be increased in cases of cardiogenic shock<sup>20, 21)</sup>. Elevation of the PCT level has also been reported in patients with burns in the respiratory tract<sup>5)</sup>.

In cases of acute pancreatitis, it has been reported that the possibility of infectious necrosis must be borne in mind when elevation of the serum PCT levels to 1.8 ng/mL or more persists for more than 2 days<sup>14, 22)</sup>. In our present study, the PCT level determined immediately after the diagnosis of the disease reflected the severity of the disease well. The serum PCT level determined immediately after the onset of acute pancreatitis was significantly higher in the patients who developed MODS and in those who eventually died. These findings suggest that the serum PCT level determined immediately after the onset of acute pancreatitis is a very reliable predictor of the prognosis in these patients.

When endotoxin was administered to healthy subjects, symptoms of SIRS, such as chills, rigidity, myalgia and fever appeared. The TNF-

$\alpha$  production peaked within 1 or 2 hours, and decreased to the baseline level within about 6 hours. The IL-6 level peaked within 3 hours, and decreased to the baseline level within about 8 hours. On the other hand, the PCT level began to increase at around 4 hours after the endotoxin administration, reached a plateau within about 6 hours, and remained at this level for about 24 hours<sup>20)</sup>. In our present study, the endotoxin level in the blood was almost consistently within the normal range, suggesting that the elevated PCT production was not likely to be the result of endotoxin stimulation. However, since a significant correlation was observed between the serum TNF- $\alpha$  level and the serum PCT level, it is possible that TNF- $\alpha$  induced the PCT production.

In the future, the association between the changes in the condition of the patient and the PCT level need to be examined on the basis of continuous determination of the PCT level.

#### Acknowledgement

This study was supported by grants from the Mutual Aid Corporation for Private School of Japan, and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

#### References

- 1) Zajac, J.D., Martin, T.J., Hudson, P.: Biosynthesis of calcitonin by human lung cancer cells. *Endocrinol* **116** : 749 - 755, 1985.
- 2) Assicot, M., Gendrel, D., Carsin, H. et al.: High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* **341** : 515 - 518, 1993.
- 3) Gramm, H.-J., Dollinger, P., Beier, W.: Procalcitonin - ein neuer Marker der inflammatorischen Wirtsantwort Longitudinalstudien bei Patienten mit Sepsis und Peritonitis. *Chir. Gastroenterol.* **11** : S51 - S54, 1995.
- 4) Gendrel, D., Assicot, M., Raymond, J. et al.: Procalcitonin as a marker for the early diagnosis of neonatal infection. *J. Pediatr.* **128** : 570 - 573, 1996.
- 5) Carsin, H., Assicot, M., Ferger, F. et al.: Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF- $\alpha$  and endotoxin levels early after thermal injury. *Burns* **23** : 218 - 224, 1997.
- 6) Sachse, C., Machens, H.G., Felmerer, G.: Procalcitonin as a marker for the early diagnosis of severe infection after thermal injury. *J Burn Care Rehabil* **20** : 354 - 360, 1999.
- 7) Kuse, E.R., Langefeld, I., Jaeger, K., et al.: Procalcitonin-a new diagnostic tool in complications following liver transplantation. *Intensive Care Med.* **26** : S187 - S192, 2000.

- 8) Miura, M., Endo, S., Inada, K. et al.: Tumor necrosis factor  $\alpha$  and NOx levels in patients with pancreatitis. *Crit. Care & Shock* **3** : 189 - 194, 2000.
- 9) Endo, S., Inada, K., Inoue, Y. et al.: Nuclear matrix protein increased in patients with pancreatitis. *J. Medicine* **31** : 320 - 326, 2000.
- 10) Miura, M., Endo, S., Kaku, L. et al.: Plasma type II PLA2 levels in patients with acute pancreatitis. *Res. Commun. Molec. Pathol. Pharmacol.* **109** : 65 - 72, 2001.
- 11) Nakae, H., Endo, S., Inoue, Y. et al.: Chronological changes in the serum levels of endothelin-1 in patients with acute pancreatitis. *Crit. Care & Shock* **3** : 141 - 144, 2001.
- 12) Bertsch, T., Richter, A., Holfheinz, H. et al.: Procalcitonin. A new marker for acute phase reaction in acute pancreatitis. *langenbecks Archiv fur Chirurgie* **382** : 367 - 372, 1997.
- 13) Oezcueruemez-Porsch, M., Kunz, D., Hardt, P.D. et al.: Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. *Digestive Diseases & Sciences* **43** : 1763 - 1769, 1998.
- 14) Rau, B., Steinbach, G., Baumgart, K. et al.: The clinical value of procalcitonin in the prediction of infected necrosis in acute pancreatitis. *Intensive Care Med* **26** : S159 - S164, 2000.
- 15) Kylanpaa, M.L., Takala, A., Kemppainen, E.A.: Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis. *Crit.Care Med.* **29** : 63 - 69, 2001.
- 16) Ranson, J.H.C.: Acute pancreatitis: surgical management. In *The Pancreatitis: Biology, Pathobiology and Disease*. Second Edition. edited by go VLW et al. Raven Press, New York, pp637-648, 1993.
- 17) ACCP/SCCM: Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee *Chest* **101** : 1644 - 1655, 1992./*Crit Care Med* **20** : 864 - 874, 1992.
- 18) Nylen, E.S., Snider, R.H., Thompson, K.A. et al.: Pneumonitis-associated hyperprocalcitoninemia. *Am J Med Sci* **312** : 12 - 18, 1996.
- 19) Mimoz, O., Benoist, J.F., Edouard, A.R. et al.: Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. *Intensive Care Med.* **24** : 185 - 188, 1998.
20. De Werra, I., Jaccard, C., Corradin, S.B. et al.: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentration: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. *Crit Care Med* **25** : 607 - 613, 1997.
- 21) Brunkhorst, F.M., Clark, A.L., Forycki, Z.F. et al.: Pyrexia, procalcitonin, Immune activation and survival in cardiogenic shock. *J. Int. Cardiol.* **72** : 3 - 10, 1999.

## Procalcitonin level as a reliable indicator of the severity of abdominal sepsis

Masanori Hakozaiki*	Nobuhiro Sato*	Takeshi Kasai*
Yasushi Suzuki*	Masaaki Ogawa*	Masahiro Kojika*
Gaku Takahashi*	Satoko Imai*	Michiko Miyata*
Yoriko Ishibe*	Satoshi Kikuchi*	Shigehiro Shibata*
Nobuki Shioya*	Yasunori Yaegashi*	Shigeatsu Endo*

**Abstract :** We determined the serum levels of procalcitonin (PCT), a precursor of calcitonin, in patients with abdominal sepsis as a marker for an infectious diagnosis.

**Methods :** The subjects consisted of 11 patients with sepsis, 14 patients with severe sepsis, and 10 patients with septic shock. The PCT level in the sepsis group ( $4.3 \pm 2.3$  ng/mL) was significantly lower than that in the severe sepsis group ( $9.7 \pm 2.7$  ng/mL), and the level in the septic shock group ( $36.5 \pm 28.4$  ng/mL) was significantly higher than that in the severe sepsis group. A significant correlation was thus observed between the PCT level and the sepsis-related organ failure assessment score (SOFA score). These findings suggest that the serum level of PCT may faithfully reflect the severity of abdominal sepsis.

**Key words :** procalcitonin, abdominal sepsis, severity, IL-6, CRP

### I. Introduction

We reported previously that numerous mediators are produced in cases of infection, especially in conditions complicated by sepsis<sup>1)</sup>. Among these, inflammatory cytokines are known to play particularly important role.

Procalcitonin (PCT) is a precursor of the peptide hormone, calcitonin, and its molecular weight is about 13 kD.<sup>2)</sup> Recently, measurements of the PCT levels in the serum have been reported to be useful for the diagnosis of infection or sepsis<sup>3~10)</sup>.

In this study, we determined the levels of

inflammatory cytokines and PCT in cases of abdominal sepsis, and examined their association with the severity of the condition.

### II. Materials and Methods

Thirty-five patients with abdominal sepsis were studied. The diagnosis and the severity of the condition in the study cases are presented in **Table 1**.

The mean age of the patients was  $68.4 \pm 11.2$  years. They consisted of 23 males ( $69.0 \pm 11.2$  years) and 12 females ( $67.1 \pm 11.7$  years). There was no significant difference in the mean age

Masanori Hakozaiki et al.: \*Department of Critical Care Medicine, School of Medicine, Iwate Medical University, Morioka, Japan

**Table 1** Diagnosis in patients who developed Sepsis, severe sepsis, and septic shock

	Sepsis	Severe sepsis	Septic shock	Total
Pancreatitis	2	3		5
Biliary peritonitis	2	2	1	5
Colon perforation	3	4	4	11
Mesenteric infarction	1	2	2	5
Traumatic peritonitis	1	1	1	3
Postoperative peritonitis	2	2	2	6
Total	11	14	10	35

between the male and female patients.

The criteria of Bone et al. were used for the classification into sepsis, severe sepsis and septic shock<sup>11)</sup>.

Eleven patients were categorized into the sepsis group ( $65.6 \pm 13.9$  years), 14 into the severe sepsis group ( $70.4 \pm 11.0$  years), and 10 into the septic shock group ( $68.8 \pm 8.4$  years). There was no significant difference in the mean age among the three groups.

To determine the levels of PCT, tumor necrosis factor  $\alpha$ , (TNF- $\alpha$ ) and interleukin 6 (IL-6), the serum was separated immediately after the collection of the blood samples, and preserved at  $-80^{\circ}\text{C}$ . The serum CRP level was then determined immediately after the collection of blood samples.

The serum PCT level was determined by a chemoluminescence immunoassay (LUMI test PCT<sup>TM</sup>, BRAHMS Diagnostica GmbH, Berlin, Germany). The detection limit was 0.1 ng/mL.

The serum TNF- $\alpha$  level was determined by an enzyme-linked immunosorbent assay (ELISA) (Medgenix Diagnostics, Fleurus, Belgium). The detection limit was 3 pg/mL.

The serum IL-6 level was also determined by ELISA (TFB Co. Ltd., Tokyo, Japan), and the detection limit was 10 pg/mL.

The serum CRP level was determined immediately after isolation of the serum by Latex Enhanced Turbidimetric Reagents

(Immunoticles Auto CRP, A&T Corporation, Kanagawa, Japan). Normal range, less than 0.3 mg/dL.

The SOFA score was used as an indicator of the severity of sepsis<sup>12)</sup>.

Mann-Whitney's U test was used to examine the differences between two groups. Pearson's equation was used to test the correlations. For both, the level of significance was defined as  $p < 0.05$ .

### III. Results

#### 1. PCT levels

The serum PCT level was  $4.6 \pm 2.3$  ng/mL in the sepsis group and  $9.7 \pm 2.7$  ng/mL in the severe sepsis group, and thus it was significantly higher in the former group. The PCT level in the septic shock group was  $36.5 \pm 28.4$  ng/mL, which was significantly higher than that in the severe sepsis group (Fig. 1).

#### 2. IL-6 levels

The serum IL-6 level in the sepsis group was  $32.0 \pm 14.9$  pg/mL and that in the severe sepsis group was  $108.2 \pm 54.9$  pg/mL, with the former being significantly higher than the latter. The IL-6 level in the septic shock group was  $254.5 \pm 304.2$  pg/mL, which was significantly higher than that in the sepsis group, but not significantly different from that in the severe sepsis group (Fig. 2).




Fig. 1 PCT levels in patients with abdominal sepsis.




Fig. 2 IL-6 levels in patients with abdominal sepsis.

### 3. TNF- $\alpha$ levels

The serum TNF- $\alpha$  level was  $36.0 \pm 26.0$  pg/mL in the sepsis group and  $81.4 \pm 28.5$  pg/mL in the severe sepsis group, with the level in the

former group being significantly higher than that in the latter group. The TNF- $\alpha$  level in the septic shock group was  $146.6 \pm 96.1$  pg/mL, which was significantly higher than that in the




Fig. 3 TNF- $\alpha$  levels in patients with abdominal sepsis.




Fig. 4 CRP levels in patients with abdominal sepsis.

severe sepsis group (Fig. 3).

#### 4. CRP levels

The serum CRP level was  $10.0 \pm 3.4$  mg/dL in the sepsis group and  $16.1 \pm 3.9$  mg/dL in the






Fig. 5 The correlation between SOFA score and PCT levels.

Table 2 Mean values for patients who survived and nonsurvived

	Survivors (n = 28)	Nonsurvivors (n = 7)	P value
PCT (ng/mL)	11.6 ± 11.7	31.6 ± 36.0	0.0167
TNF- $\alpha$ (pg/mL)	77.1 ± 61.7	146.1 ± 99.8	0.0373
IL-6 (pg/mL)	104.3 ± 157.6	213.1 ± 259.3	0.0832
CRP (mg/mL)	141.1 ± 5.0	18.9 ± 8.9	0.2232
SOFA score	3.8 ± 3.5	11.3 ± 2.6	0.0003

severe sepsis group, and thus it was significantly higher in the former group. The serum CRP level in the septic shock group was  $19.3 \pm 7.4$  mg/dL, which was significantly higher than that in the sepsis group, but not significantly different from that in the severe sepsis group (Fig. 4).

#### 5. SOFA scores and PCT levels

A significant correlation was observed between the SOFA scores and the serum PCT levels (Fig. 5).

The SOFA score exhibited significant correlations with the serum IL-6, TNF- $\alpha$  and CRP levels ( $r = 0.3487$ ,  $p = 0.0401$ ;  $r = 0.7009$ ,  $p < 0.0001$ ;  $r = 0.4011$ ,  $p = 0.0169$ ).

#### 6. Comparison of the various parameters in the patients who survived and those who died during the study period

When the patients who survived and patients who died during the study period were compared, the PCT level, TNF- $\alpha$  level and SOFA score were found to be significantly higher in the patients who died (Table 2).

#### IV. Discussion

Numerous cells, including monocytes and macrophages, produce cytokines, but the cells producing PCT have not been identified yet. An elevation of the serum PCT level triggered by infection has been reported in patients even after a total thyroidectomy<sup>9</sup>.

When endotoxin is administered to healthy subjects, the symptoms of SIRS, such as chills, rigidity, myalgia and fever appear. The TNF- $\alpha$  production peaks about 1 or 2 hours after the endotoxin administration, and decreases to the baseline level within about 6 hours. The IL-6 level peaks within 3 hours of endotoxin administration and decreases to the baseline level within about 8 hours. On the other hand, PCT becomes detectable in the serum about 4 hours after endotoxin administration, thereafter it begins to plateau at about 6 hours after the administration, and then remains at this level for about 24 hours<sup>10)</sup>.

Our present study revealed that both the PCT and TNF- $\alpha$  levels, in particular, the former, faithfully reflect the severity of abdominal sepsis. However, the serum IL-6 and CRP levels did not reliably reflect the severity of abdominal sepsis.

An elevation of the serum PCT level has also been reported in malaria<sup>4)</sup>, and melioidosis<sup>6)</sup>, with the latter caused by a Gram-negative bacillus. In both conditions, a greater elevation

has been reported in more severe cases.

Our present study was confined to patients with abdominal sepsis. However, determination of the serum level of PCT appeared to be more useful than that of the serum levels of CRP, TNF- $\alpha$  and IL-6 for accurately diagnosing a bacterial infection, in general, and for assessing its severity, although it was not necessarily a specific method for the diagnosis.

We herein described the usefulness of determining the serum levels of PCT to estimate the severity of abdominal sepsis. In the future, the serum levels of PCT need to be examined in a larger subject population with sepsis caused by different types of bacteria, in order to determine the sensitivity and specificity of determining the PCT levels in order to make an accurate diagnosis of sepsis.

#### Acknowledgement

This study was supported by grants from the Mutual Aid Corporation for Private Schools of Japan, and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

#### References

- 1) Takakuwa, T., Endo, S., Inada, K. et al.: Assessment of inflammatory cytokines, nitrite/nitrate, type II phospholipase A<sub>2</sub>, and soluble adhesion molecules in systemic inflammatory response syndrome. *Res Commun Molecul Pathol Pharmacol* **98** : 43 - 52, 1997.
- 2) Zajac, J.D., Martin, T.J., Hudson, P. et al.: Biosynthesis of calcitonin by human lung cancer cells. *Endocrinol* **116** : 749 - 755, 1985.
- 3) Assicot, M., Gendrel, D., Carsin, H. et al.: High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* **341** : 515 - 518, 1993.
- 4) Davis, T.M.E., Assicot, M., Bohuon, C. et al.: Serum procalcitonin concentrations in acute malaria. *Trans R Soc Med Hyg* **88** : 670 - 671, 1994.
- 5) Smith, M.D., Suputtamongkol, Y., Chaowagul, W. et al.: Elevated serum procalcitonin levels in patients with melioidosis. *Clin Infect Dis* **20** : 641 - 645, 1995.
- 6) Reith, H.B., Lehmkuhl, R., Beier, W. et al.: ein prognostischer Infektionsparameter bei der Peritonitis. *Chir Gastroenterol* **7** (Suppl 2) : 47 - 50, 1995.
- 7) Gramm, H.-J., Dollinger, P. and Beier, W.: Procalcitonin - ein neuer Marker der inflammatorischen Wirtsantwort. *Longitudinalstudien bei Patienten mit Sepsis und Peritonitis. Chir Gastroenterol* **11** (Suppl 2) : 51 - 54, 1995.
- 8) Gendrel, D., Assicot, M., Raymond, J. et al.: Procalcitonin as a marker for the early diagnosis of neonatal infection. *J Pediatr* **128** : 570 - 573, 1996.
- 9) Nylen, E.S., Snider, R.H., Thompson, K.A. et al.: Pneumonitis-associated hyperprocalcitoninemia. *Am J Med Sci* **312** : 12 - 18, 1996.
- 10) DeWerra, I., Jaccard, C., Corradin, S.B. et al.: Cytokine, nitrite/nitrate, soluble tumor necrosis

- factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med **25** : 607 - 613, 1997.
- 11) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest **101** : 1644 - 1655, 1992./ Crit Care Med **20** : 864 - 874, 1992.
- 12) Vincent, J.L., Moreno, R., Takala, J. et al.: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive care Med. **22** : 707 - 710, 1996.
-

## プロカルチトニン値は敗血症時の組織酸素代謝と 皮下血流量を反映する

小鹿 雅博\* 佐藤 信博\* 菊地 充\* 鈴木 泰\*  
小川 雅彰\* 箱崎 将規\* 高橋 学\* 宮田美智子\*  
菊池 哲\* 磯野 寿育\* 塩谷 信喜\* 柴田 繁啓\*  
葛西 健\* 遠藤 重厚\*

要 旨：敗血症時の血中のプロカルチトニン値と末梢循環の指標として皮下血流量を、組織酸素代謝の指標の指標として胃粘膜pH (pHi) を測定した。プロカルチトニン値と皮下血流量、pHi値間には有意の負の相関関係がみられ、プロカルチトニン値が末梢循環および組織酸素代謝を良く反映していることがわかった。また、プロカルチトニンとSOFAスコア間には有意の相関関係がみられ、プロカルチトニン値は病態の重症度も良く反映していることが判った。

**Key words :** プロカルチトニン, 敗血症, 胃粘膜pH, 皮下血流量, SOFAスコア

### はじめに

プロカルチトニン (procalcitonin: PCT) はペプチドホルモンであるカルチトニン (calcitonin) の前駆体で、その分子量は約13kDである<sup>1)</sup>。最近、PCTが感染症あるいは敗血症の診断に有用であるとの報告が欧米においてみられる<sup>2-9)</sup>。我々も敗血症診断法としてPCTを測定する事の有用性について報告してきた<sup>10-12)</sup>。また、PCT値は敗血症における重症度も良く反映する<sup>11-13)</sup>。

我々は、敗血症時の末梢循環の指標として皮下血流量を、組織酸素代謝の指標の指標として胃粘膜pHを測定し、両者間に有意の相関関係がみられることを報告した<sup>14)</sup>。

今回、敗血症においてプロカルチトニン値と皮下血流量および胃粘膜pHとの関連について検討した。

### 対象および方法

対象は汎発性腹膜炎に敗血症を合併した3例である。敗血症の診断はACCP/SCCM Consensus Conferenceによった<sup>15)</sup>。

重症度の指標としては、sepsis-related organ failure assessment (SOFA) スコア<sup>16)</sup>を用いた。

PCTの定量は化学発光免疫測定法 (LUMI test PCT™, B・R・A・H・M・S DIAGNOSTICA GmbH, Berlin, Germany, Lumico Analyzer SA-300, マイクロテック, ニチオン, 東京) により測定した。その測定限界値は0.1ng/mLであり、敗血症は2ng/mL以上としている<sup>17)</sup>。

胃粘膜pH (pHi) はgastrointestinal tonometer and sump tube; TGS, トノメトリック社, USA) を用いて測定した。

皮下血流量は、レーザードップラー法で測定した (Advance laser flow meter; Alfa 2100, アド

Masahiro Kojika et al.: Procalcitonin level reflects the tissue oxygen metabolism and dermal blood flow in sepsis.

\*岩手医科大学医学部 救急医学




図1 60歳代の男性。直腸穿孔による汎発性腹膜炎に敗血症を合併した。手術後症状は軽快した。




図2 60歳代の女性。後腹膜膿瘍後の敗血症性多臓器不全症候群で死亡した。

バンス社，東京)。測定は肘関節から3分の1の前腕背側にプローベを装着・固定し行った。

相関関係はPearsonの式を用いて行い， $p < 0.05$ で有意差ありとした。

## 結 果

症例1：70代の男性。直腸穿孔による腹膜炎に敗血症性ショック，汎発性血管内凝固症候群，急性呼吸促迫症候群を合併していた。術後のpHi値は7.39以下で推移していたが，症状の軽快に伴い上昇した。皮下血流量は2.6mL/min/dLから上

昇を示した。一方，PCT値は敗血症性ショック時に38.6ng/mLと上昇したが，症状の改善に伴い著明に低下した（図1）。

症例2：60歳代の女性。後腹膜膿瘍による敗血症性ショックで紹介入院となった。手術施行するも5病日には敗血症性多臓器不全症候群を併発し，8病日目に死亡した。PHi値の低下とともに皮下血流量も入院時3.0mL/min/dLから2.0mL/min/dL前後に低下した。PCT値は入院時10.3ng/mLで，死亡時は29.8ng/mLまで上昇した（図2）。




図3 70歳代の男性。S状結腸穿孔後の敗血症から離脱した。




図4 PCT値と皮下血流量値間には有意な負の相関関係が認められる。

症例3：70歳代の男性。S状結腸穿孔後の敗血症性ショックの患者である。来院時のPCT値は12.8ng/mL、pHiは7.38、皮下血流量は2.8mL/min/dLであった。病態の改善に伴い、PCT値は低下し、一方pHiおよび皮下血流量は増加した(図3)。

3症例の全測定ポイントのPCT値とpHi値間には有意な負の相関関係がみられた( $r = -0.6791$ ,  $p = 0.0002$ )(図4)。

3症例の全測定ポイントのPCT値と皮下血流量

値間には有意な負の相関関係がみられた( $r = -0.5354$ ,  $p = 0.0058$ )(図5)。

また、pHi値と皮下血流量値間にも有意の相関関係がみられた( $r = 0.6183$ ,  $p = 0.0010$ )。

PCT値とSOFAスコア間にも有意の相関関係がみられた( $r = 0.8185$ ,  $p < 0.0001$ )

## 考 察

PCT値は敗血症の重症度を良く反映することは、これまで報告してきたが<sup>11~13)</sup>、今回の検討




図5 pHi値と皮下血流量値には有意な負の相関関係が認められる。

でも同様な結果が得られてた。

pHiは病態の変化に応じて変動した。死亡例においては低値で推移し、生存例においては全身状態の改善に伴い、すなわちSOFAスコアの改善に伴いpHi値は上昇し7.4以上まで上昇することが認められた。pHiが組織酸素代謝不全の良い指標となるとの報告がある<sup>18, 19)</sup>。pHiが低値であるときは、組織における低酸素血症の状態であることが窺われる<sup>20)</sup>。PCT値とpHi値間に有意の相関関係がみられることは、胃粘膜pHをPCT値が反映していることであり、PCT値が組織酸素代謝をも反映していることを意味している。

レーザードップラー法による皮下血流量も我々の以前の報告<sup>14)</sup>と同様の結果が得られ、pHiと同様の推移を示した。また、PCT値とも有意の相関関係がみられた。このことはPCT値が敗血症において末梢循環、組織酸素代謝の指標の一つとなりうる可能性を示しているものと思われる。

一方で、PCTを投与するとショックを惹起して死亡率が増加し、抗PCT血清を投与すること

により生存率が増すとの報告もある<sup>21)</sup>。このことはPCTそのものが、循環動態の変動に関与している可能性が窺われる。また、interleukin 2 (IL-2) を投与するとPCTが産生されるとの報告もある<sup>22)</sup>。我々は、ヒトの敗血症性ショック時にtumor necrosis factor  $\alpha$ 、IL-2が上昇し、ショック発現に関与している可能性について報告しているが、敗血症性ショック時にはPCTも上昇することからも、PCTがショック発現に直接係わる生理作用を有している可能性も窺われる。

しかし、測定値が乖離した値を示す場合があることが認められたが、その原因の一つとしてTGSの位置不良や皮膚温や発汗などによるプローベへの外的因子の関与が考えられた<sup>24)</sup>。

#### 謝 辞

本研究の一部は、厚生労働科学研究費補助金、文部科学省科学研究費、および日本私立学校振興・共済事業団の助成によった。

## 文 献

- 1) Zajac, J.D., Martin, T.J., Hudson, P. et al.: Biosynthesis of calcitonin by human lung cancer cells. *Endocrinol* **116** : 749 - 755, 1985.
- 2) Assicot, M., Gendrel, D., Carsin, H. et al.: High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* **341** : 515 - 518, 1993.
- 3) Davis, T.M.E., Assicot, M., Bohuon, C. et al.: Serum procalcitonin concentrations in acute malaria. *Trans R Soc Med Hyg* **88** : 670 - 671, 1994.
- 4) Smith, M.D., Suputtamongkol, Y., Chaowagul, W. et al.: Elevated serum procalcitonin levels in patients with melioidosis. *Clin Infect Dis* **20** : 641 - 645, 1995.
- 5) Reith, H.B., Lehmkuhl, R., Beier, W. et al.: die Studiengruppe Peritonitis : Procalcitonin - ein prognostischer Infektionsparameter bei der Peritonitis. *Chir Gastroenterol* **7** (Suppl 2) : 47 - 50, 1995.
- 6) Gramm, H-J., Dollinger, P., Beier, W.: Procalcitonin - ein neuer Marker der inflammatorischen Wirt-santwort Longitudinalstudien bei Patienten mit Sepsis und Peritonitis. *Chir Gastroenterol* **11** (Suppl 2) : 51 - 54, 1995.
- 7) Gendrel, D., Assicot, M., Raymond, J. et al.: Procalcitonin as a marker for the early diagnosis of neonatal infection. *J Pediatr* **128** : 570 - 573, 1996.
- 8) Nylen, E.S., Snider, R.H., Thompson, K.A. et al.: Pneumonitis-associated hyperprocalcitoninemia. *Am J Med Sci* **1312** : 12 - 18, 1996.
- 9) Werra, I., Jaccard, C., Corradin, S.B. et al.: Cytokine, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. *Crit Care Med* **25** : 607 - 613, 1997.
- 10) 遠藤重厚, 葛西 健, 高桑徹也ほか: 感染症診断としてのProcalcitonin測定の意義. *日本外科感染症研究* **10** : 179 - 183, 1998.
- 11) 遠藤重厚, 葛西 健, 稲田捷也: 全身性炎症反応症候群における感染症および重症度診断としてのプロカルチトニン値測定の意義. *感染症誌* **73** : 197 - 203, 1999.
- 12) Kitamura, M., Endo, S., Sato, N. et al.: Procalcitonin levels in the blood reliably reflect the severity of diffuse peritonitis. *Medical Postgraduates* **42** : 159 - 163, 2004.
- 13) 遠藤重厚, 佐藤信博, 鈴木 泰ほか: プロカルチトニン値はエンドトキシン吸着療法時の重症度をよく反映する: 症例報告. *Medical Postgraduates* 2007 (印刷中)
- 14) 菊地 充, 遠藤重厚, 荒川直志ほか: 敗血症症例におけるpHiによるtissue oxygen metabolismとレーザードップラー法による皮下血流の相関について. *日救急医学会誌* **6** : 366 - 367, 1995.
- 15) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* **101** : 1644 - 1655, 1992./ *Crit Care Med* **20** : 864 - 874, 1992.
- 16) Vincent, J.L., Moreno, R., Takala, J.: The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/ failure. *Intensive Care Med* **22** : 707 - 710, 1996.
- 17) Karzai, W., Oberhoffer, M., Meier-Hellmann, A. et al.: Procalcitonin - A new indicator of the systemic response to severe infections. *Infection* **25** : 329 - 334, 1997.
- 18) Fiddéan-Green, R.G., Baker, S.: The predictive value of measurement of pH in the wall of the other forms of monitoring. *Crit Care Med* **15** : 153 - 156, 1987.
- 19) Gys, T., Hubens, A., Neels, H. et al.: Prognostic value of gastric intramural pH in surgical intensive care patients. *Crit Care Med* **16** : 1222 - 1224, 1988.
- 20) Gutierrez, G., Clark, C., Brown, S.D. et al.: Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. *Am J Respir Crit Care Med* **150** : 324 - 329, 1994.
- 21) Nylen, E.S., Whang, K.T., Snider, R.H. et al.: Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. *Crit Care Med* **26** : 1001 - 1006, 1998.
- 22) Guidet, B., Staikowsky, F., Offenstadt, G.: Interleukines et TNF dans le choc septique. *Rev Prat* **43** : 13 - 17, 1993.
- 23) Endo, S., Inada, K., Inoue, Y. et al.: Two types of septic shock classified by the plasma levels of cytokines and endotoxin. *Circ Shock* **36** : 264 - 274, 1992.
- 24) 杉原 浩, 成田信義, 松井豊祐ほか: レーザードップラー法による定量的皮膚血流量測定と健康者についての検討. *日臨生学会誌* **22** : 345 - 349, 1992



## 敗血症に対する抗TNFモノクローナル抗体投与時の プロカルチトニン値の推移：症例報告

遠藤重厚\* 葛西 健\* 佐藤信博\* 鈴木 泰\*  
小鹿雅博\* 高橋 学\* 宮田美智子\* 菊池 哲\*  
松本尚也\* 小豆島立頼\* 柴田繁啓\* 山田裕彦\*  
八重樫泰法\*

要 旨：症例は70歳代の男性である。敗血症性ショックにTNF- $\alpha$ のモノクローナル抗体を投与した。血中のTNF- $\alpha$ 、IL-6およびNOx値が低下した。感染症の診断マーカーとして有望なプロカルチトニン値は、敗血症性ショック時に上昇し、症状の改善に伴い低下が認められ、重症度と良い相関関係が認められた。

**Key words** : 抗TNF抗体, プロカルチトニン, 敗血症, サイトカイン, 一酸化窒素

### I. はじめに

バイオテクノロジーが進歩した過去30年間に、敗血症の病態生理に関係するいくつかの特異的炎症性メディエータが報告された。Tumor necrosis factor (TNF) は敗血症発症との関連性が明らかとなった最初のサイトカインである。BeutlerとCeramiは慢性感染症患者に認められる重度の体重減少(悪液質)の原因を探るうちにこの関連性を見出した<sup>1)</sup>。彼らは単球由来因子が原因であると判断した。引き続きこのタンパク質をクローン化し、配列決定を行い、同一の腫瘍壊死因子であることを突き止めた。敗血症の発症におけるカケクチン/TNFの作用を検討するため、Beutlerらはlipopolysaccharide (LPS) の作用に抵抗する系統のマウスが、LPSに应答してTNFを合成しないことを示した<sup>2)</sup>。さらにLPS-抵抗性マウスにTNFを静注すると、正常マウスへのLPS静注と同様に、敗血症の病態生理が再現され

ることを示した。TNF- $\alpha$ のモノクローナル抗体(TNFMab)については9件の臨床試験が公表されている<sup>3~11)</sup>。本邦においても、1991年からヒトに対するTNF-Mabの治験が行われた。今回は、そのうちで敗血症の診断あるいは重症度の判定に有用であるといわれるプロカルチトニン(procalcitonin: PCT)<sup>12~14)</sup>を測定した症例を経験したので報告する。

### II. 方 法

本試験は、家族の同意を得るとともに岩手医科大学倫理委員会の承認を得て行った。

今回投与したTNF  $\alpha$  MAbはBAYx1351 (Bayer Corporation, Berkeley, CA) である。本剤は、recombinantヒトTNFで免疫されたマウス脾臓細胞とマウス骨髓腫細胞とを融合して得られるハイブリドーマA10G10の培養上清液から精製され、TNFによる細胞毒性を完全に中和する。

Shigeatsu Endo et al.: Procalcitonin levels in a septic patient by infusion of monoclonal antibodies to human tumor necrosis factor  $\alpha$ : A case report.

\*岩手医科大学医学部 救急医学




図1 BAYx 1351投与後のPCT, TNF- $\alpha$ , IL-6, NOx値の推移

本症例においては、BAYx1351は3 mg/kgを30分間で1回だけ投与した。

PCTは化学発光免疫測定法 (LUMI test PCT<sup>TM</sup>, B・R・A・H・M・S DIAGNOSTICA GMBH, Berlin, Germany) により測定した。2 ng/mL以上を敗血症としている。

各種サイトカインはいずれもenzyme-linked immunosorbent assay (ELISA) で測定した。TNF- $\alpha$ はMedogenix社製 (Fleurus, Belgium), Interleukin 6 (IL-6)はTFB社製 (Tokyo, Japan) を用いた。

NOの最終代謝産物であるnitrite/nitrate (NOx)はGriess法により自動分析器 (TCI-NOX 1000; Tokyo Kasei Kogyo Co., Ltd., Tokyo) で測定した<sup>15)</sup>。

エンドトキシン値はエンドトキシン特異的な高感度法で測定した<sup>16)</sup>。

敗血症の診断はsystemic inflammatory response syndrome (SIRS)を決めたACCP/SCCMの基準を用いた<sup>17)</sup>。

重症度の指標としては、acute physiology and chronic health evaluation II (APACHE II) スコアを用いた<sup>18)</sup>。

disseminated intravascular coagulation (DIC)の診断は急性期のDIC診断基準を用いた<sup>19)</sup>。

### Ⅲ. 症 例

症 例：70歳代の男性

既往歴：前立腺腫瘍で13年前に手術施行している。

臨床経過：1992年3月2日3時にショック状態で紹介となった。来院時収縮期血圧84mmHg, 心拍数120回/分, 呼吸数28回/分, 体温38.8度, 白血球数4,300/mm<sup>3</sup>とSIRSの3項目を満たす敗血症性ショック状態であった。血小板数は72,000/mm<sup>3</sup>, PT比1.26, FDP 22.6mg/mLとDICスコアは6点であった。診断は尿路感染症からの敗血症性ショックであった。血中エンドトキシン値は28.6pg/mLと高値を示し, 喀痰, 尿からは*Pseudomonas aeruginosa*が検出された。5時よりBAYx1351 3 mg/kgを30分かけて静注した。BAYx1351投与により, 速やかに症状の改善を見た。PCT, TNF- $\alpha$ , IL-6, NOx値も速やかに低下した (図1)。APACHE IIスコアとPCT値間には有意の相関関係が認められた (図2)。




図2 BAYx1351投与後のPCT値とAPACHE IIスコアの相関関係

#### IV. 考 察

支持療法や医療技術の進歩にもかかわらず重症敗血症の死亡率は依然として高い(30~35%)<sup>20)</sup>。

敗血症の発症におけるTNFに関して以下の事実が明白である：(1) TNFはLPS静注動物で検出される，(2) TNF欠乏動物はLPSの作用に耐容性を示す，(3) 動物へのTNF静注はLPS静注と同様の病態生理を示す，(4) TNF抗体はLPS静注による有害反応を阻止する。髄膜炎菌血症患者における血漿TNF濃度と生存率の逆相関は，TNFが敗血症の発症において主要な働きをすることを強く示唆するもう1つの指標である<sup>21)</sup>。

敗血症におけるTNFをターゲットしてTNF-MAbが開発されて，海外において9つの治験が，本邦においても第I相治験が行われたがその結果は必ずしも期待したものではなかった。しかし，最近羊のTNF-MAb投与に関する報告がなされ，臨床的効果を認めている<sup>22)</sup>。

一方，PCT値は急性期における重症感染症の

有望マーカーとなっている。それらの状況下において，敗血症治療に有効であると同時に治療が有効である時には，プロカルシトニン濃度を低下に導く。

今回，TNF-MAbの治療効果をPCT値の変化で検討したが，TNF-MAb投与直前にPCT値は3.4ng/mLまで上昇していたが，TNF-MAb投与によるTNF- $\alpha$ ，IL-6の低下に伴い，PCT値も低下した。PCT値はAPACHE IIスコアと強い相関関係が認められ，重症度を良く反映していることが認められた。一酸化窒素はショックの本体と言われているが，NO<sub>x</sub>の低下に伴い血圧の上昇も見られ，早期にショックから離脱した。本症例においては，敗血症性ショックの診断からTNF-MAb投与までの時間が2時間と早期の投与が可能であったことが良い結果をもたらしたと思われる。本薬剤の使用法について示唆を与える症例であったと思われる。

#### 文 献

- 1) Beutler, B. and Cerami, A.: Cachectin: more than a tumor necrosis factor. *N Eng J Med* **316** : 379 - 385, 1987.
- 2) Beutler, B. and Cerami, A.: The biology of cachectin/TNF- $\alpha$  primary mediator of the host response. *Ann Rev Immunol* **7** : 625 - 655, 1989.

- 3) Zeni, F., Freeman, B. and Natanson, C.: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. *Crit Care Med* **25** : 1095 - 1100, 1997.
- 4) Abraham, E., Wunderink, R., Silverman, H. et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor- $\alpha$  in patients with sepsis syndrome. A randomized, controlled, double-blind multi-center clinical trial. TNF- $\alpha$  Mab Sepsis Study Group. *JAMA* **273** : 934 - 941, 1995.
- 5) Cohen, J. and Carlet, J.: Intersept: An international multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor - $\alpha$  in patients with sepsis. *Crit Care Med* **24** : 1431 - 1440, 1996.
- 6) Abraham, E., Anzueto, A., Gutierrez, G. et al.: Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in human septic shock. *Lancet* **351** : 929 - 933, 1998.
- 7) Clark, M., Plank, L., Connolly, A. et al.: Effect of a chimeric antibody to tumor necrosis factor  $\alpha$  on cytokine and physiologic responses in patients with severe sepsis. A randomized clinical trial. *Crit Care Med* **26** : 1651 - 1659, 1998.
- 8) Rheinhardt, K., Wiegand-Lohnart, C., Grimminger, F. et al.: Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment MAK 19F in patients with sepsis and septic shock. *Crit Care Med* **24** : 733 - 742, 1996.
- 9) Kay, C.A.: Can better measures of cytokine response be obtained to guide cytokine inhibition? Presentation and handout Washington DC, Cambridge Health Institute February 20 - 21, 1996.
- 10) Dhainaut, J., Vincent, J., Richard et. CD571, a humanized antibody to tumor necrosis factor- $\alpha$ : safety, pharmacodynamics, immune responses and influence of the antibody on cytokine concentrations in patients with septic shock. *Crit Care Med* **21** : 1461 - 1469, 1995.
- 11) Fisher, C., Opal, S., Dhainaut, J. et al.: The CB006 Sepsis Syndrome Study Group. *Crit Care Med* **21** : 318 - 327, 1993.
- 12) Assicot, M., Gendrel, D., Carsin, H. et al.: High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* **341** : 515 - 518, 1993.
- 13) 遠藤重厚, 葛西 健, 高桑徹也ほか: 感染症診断としてのProcalcitonin測定の意義. *日本外科感染症研究* **10** : 179 - 183, 1998.
- 14) 遠藤重厚, 葛西 健, 稲田 捷: 全身性炎症反応症候群における感染症および重症度診断としてのプロカルチニン値測定の意義. *感染症誌* **73** : 197 - 203, 1999.
- 15) Green, L.G., Wagner, D.A., Glogowski, J. et al.: Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. *Anal Biol*, **126** : 131 - 138, 1982.
- 16) Knaus, W.A., Draper, E.A., Wagner, D.P. et al.: APACHE II: A severity of disease classification system. *Crit Care Med* **13** : 818 - 829, 1985.
- 17) 八重樫泰法, 稲田棲也, 佐藤信博ほか: 血漿高感度エンドトキシン測定法について. *エンドトキシン血症救命治療研究会誌* **7** : 25 - 28, 2003.
- 18) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* **101**: 1644-55, 1992./ *Crit Care Med* **20** : 864 - 74, 1992.
- 19) Gando, S., Iba, T., Eguchi, Y. et al.: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. *Crit Care Med* **34** : 625 - 631, 2006.
- 20) Delinger, R.P., Carlet, J.M., Masur, H. et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* **32** : 858 - 873, 2004.
- 21) Waage, A., Halstensen, A., Espevik, et al.: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. *Lancet* **1** : 355 - 377, 1987.
- 22) Rice, T.W., Wheeler, A.P., Morris, P.E. et al.: Safety and efficacy of affinity-purified, anti-tumor necrosis factor- $\alpha$ , ovine fab for injection (CytoFab) in severe sepsis. *Crit Care Med* **34** : 2271 - 2281, 2006.
- 23) Palmer, R.M.J., Ferrige, A.G., Moncada, S.: Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. *Nature* **327** : 524 - 526, 1987.